
18th Mar 201912:30 - 14:00
For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications click hereThis promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the... Learn more »
The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response
For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications click hereThis promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the... Learn more »

19th Mar 201919:00 - 20:30
For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications click hereThis promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the... Learn more »
The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response
For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications click hereThis promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the... Learn more »

20th Mar 201919:00 - 20:30
For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications click hereThis promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the... Learn more »
The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response
For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications click hereThis promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the... Learn more »